Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Thursday broker round-up

Thu, 13th Oct 2016 13:43
(ShareCast News) - Ted Baker: Goldman Sachs keeps at buy with a target price of 3140p.Brown N: HSBC reiterates hold, 205p target.MITIE: Citigroup keeps at neutral with a 280p target.Prudential: Societe Generale reiterates outperform with a 1250p target.Astrazeneca: Jefferies keeps at buy with a 6000p target.Kier Group: JP Morgan keeps at overweight with a target price of 1570p.United Utilities: Societe Generale upgrades to buy sell with a target price of 1040p.Game Digital: Canaccord stays at hold with a 72p target.Tate & Lyle: JP Morgan reiterates neutral with a target of 770p.GlaxoSmithKline: Jefferies maintains buy with a 1950p target.DFS: Jefferies keeps at buy with a 280p target.Inmarsat: JP Morgan reiterates overweight with a 950p target. Astrazeneca Prudential Tate & Lyle Mitie Kier United Utilities

Shares in this article

Related News

AstraZeneca's Enhertu wins first EU tumour-agnostic approval for HER2
1 day ago

AstraZeneca's Enhertu wins first EU tumour-agnostic approval for HER2

(Alliance News) - AstraZeneca PLC on Monday said the European Commission has approved Enhertu as the first tumour-agnostic HER2-directed therapy and a...

LONDON BRIEFING: BT, Verizon merge international arms in joint venture
1 day ago

LONDON BRIEFING: BT, Verizon merge international arms in joint venture

(Alliance News) - BT and Verizon form international joint venture, Foresight increases its dividend while Plus500 adds to its US prediction markets of...

AstraZeneca's Datroway and Enhertu candidates receive EU approval
1 day ago

AstraZeneca's Datroway and Enhertu candidates receive EU approval

(Sharecast News) - Drugmaker AstraZeneca said on Monday that its breast cancer therapy Datroway has been recommended for approval in the EU as a first...